The investment will go toward finishing a Phase 2a clinical trial for an anti-infective to treat chronic infections in people with CF.
- Our Research Approach
- Clinical Trials
- Public Policy
- Our Advocacy Work
- Care Centers
- CFTR Modulators
- Diversity, Equity, and Inclusion
- Get Involved
- Infection Prevention and Control
- Lung Transplantation
- Patient Registry
- Researcher Resources
- (-) About the CF Foundation
Barisic will transition from current role as Chief Financial and Administrative Officer in January 2023
The Cystic Fibrosis Foundation is providing up to $5 million to develop a method to deliver a healthy copy of the CFTR gene into the lung cells of people with CF that is unlikely to trigger an immune system response.
Addressing variability in newborn screening can prevent missed diagnoses and delays in early care intervention.
CEO pledge is part of the Foundation’s ongoing commitment to strengthen the organization and better serve all people with CF
The cystic fibrosis care model is evolving to support people living longer with CF and their increasingly diverse health needs. Catalyzed by the approval of Trikafta® and the COVID-19 pandemic, this adaptive and personalized care model encompasses novel ways to connect clinicians and patients.
Carbon Biosciences is the first company to publicly launch from the Foundation’s collaboration with Longwood Fund and the first to work alongside CF Foundation researchers at the Foundation’s therapeutics lab
New modulators in development by the CF-specific company could provide unique treatment options for the underlying cause of cystic fibrosis for many people with the disease
Early stage researchers, life science entrepreneurs, and companies are encouraged to apply starting May 2
Marissa Benchea and Jeremy and Rachel Olimb to lead the Foundation’s volunteer advocacy base into a new chapter of CF